Short Interest in 20/20 Biolabs Inc (NASDAQ:AIDX) Declines By 36.0%

20/20 Biolabs Inc (NASDAQ:AIDX) was the target of a large decline in short interest during the month of June. As of June 30th, there was short interest totaling 186,863 shares, a decline of 36.0% from the June 15th total of 291,990 shares. Based on an average daily trading volume, of 424,508 shares, the days-to-cover ratio is currently 0.4 days. Currently, 1.5% of the shares of the company are short sold.

Analyst Ratings Changes

Several equities analysts have issued reports on AIDX shares. Weiss Ratings initiated coverage on shares of 20/20 Biolabs in a research note on Thursday, May 14th. They set a “sell (e-)” rating on the stock. Maxim Group assumed coverage on shares of 20/20 Biolabs in a research note on Monday, May 11th. They issued a “buy” rating and a $5.00 price target for the company. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $5.00.

20/20 Biolabs Stock Performance

Shares of AIDX stock traded down $0.00 on Friday, reaching $0.53. The stock had a trading volume of 4,640 shares, compared to its average volume of 613,571. The firm has a market cap of $6.47 million and a PE ratio of -1.89. 20/20 Biolabs has a 1 year low of $0.51 and a 1 year high of $50.00. The stock’s 50 day simple moving average is $0.85.

20/20 Biolabs (NASDAQ:AIDX) last issued its quarterly earnings data on Wednesday, May 20th. The company reported ($0.28) EPS for the quarter. The company had revenue of $0.35 million during the quarter.

20/20 Biolabs Company Profile

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.